

**Ref: ADL/SE/2025-26/23**  
**July 18, 2025**

To,  
Listing/ Compliance Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001  
**BSE CODE: 524348**

To,  
Listing/ Compliance Department  
**National Stock Exchange of India Limited,**  
“Exchange Plaza”, Plot No. C/1,  
G Block Bandra - Kurla Complex,  
Bandra (East), Mumbai – 400051  
**NSE SYMBOL: AARTIDRUGS**

Dear Sir/Madam,

**Ref:** Regulation 33 and Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**Sub:** Audited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2025 and Outcome of the Meeting of the Board of Directors held on July 18, 2025.

This is to inform you that the Board of Directors of the Company at its Meeting held on **Friday, July 18, 2025**, has *inter-alia*, considered and approved the following:

- A) The Audited Standalone and Consolidated Financial Results of the Company for the Quarter ended June 30, 2025, in this regards we enclose:
- Audited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2025.
  - Auditor's Report on the Standalone and Consolidated Financial Results for the Quarter ended June 30, 2025.

Further, please note that the Company has already made necessary arrangement to publish the financial results in the Newspapers as required under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

- B) Appointment of M/s. Mehta & Mehta (Firm Registration Number: P1996MH007500), Practicing Company Secretaries, as Secretarial Auditors of the Company in line with SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024, for a period of five consecutive years commencing from FY2025-26 till FY2029-30, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting.



**Aarti Drugs Limited**

**Manufacturers of : Bulk Drugs & Chemicals**

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax.: 022-2407 3462 / 2407 0144  
Email: admin@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

The required details pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed herewith in **Annexure - A**.

The Meeting of the Board of Directors commenced at 12:00 Noon and concluded at 4:20 PM.

Kindly take the same on record.  
Thanking you,

Yours faithfully,  
**FOR AARTI DRUGS LIMITED**

RUSHIKESH DEOLE  
**COMPANY SECRETARY & COMPLIANCE OFFICER**  
ICSI M. No.: F12932

### Annexure – A

**Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III and SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:**

Sr. No.	Particulars	Disclosure
1.	Name of the Auditor	M/s. Mehta & Mehta, Practicing Company Secretaries (Firm Registration Number: P1996MH007500) (Peer Review Number: 3686/2023)
2.	Reason for change viz. appointment, <del>re-appointment,</del> resignation, removal, death or otherwise	Appointment of M/s. Mehta & Mehta, Practicing Company Secretaries as Secretarial Auditors of the Company.
3.	Date of appointment <del>/re-appointment/</del> cessation & Term of appointment <del>/re-appointment</del>	The Board approved appointment in its meeting held on July 18, 2025 for a period of five consecutive years commencing from FY2025- 26 till FY2029-30.
4.	Brief Profile	M/s Mehta & Mehta, Practicing Company Secretaries has over 25 years of experience in legal and secretarial consultancy. The firm provides the variety of services related to Legal, Compliance, Secretarial and so on. The firm has a dedicated team for carrying out Secretarial Audit. The firm has served diversified industries.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.

Yours faithfully,

**FOR AARTI DRUGS LIMITED**

**RUSHIKESH DEOLE**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**  
ICSI M. No.: F12932



# Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel : 022-2407 2249 / 2401 9025 (30 Lines)  
Fax.: 022-2407 3462 / 2407 0144  
Email: finacc@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

## AARTI DRUGS LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE' 2025

(Rs. in lakhs except for share data)

Sr. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		30th Jun 2025	31st Mar 2025	30th Jun 2024	31st Mar 2025	30th Jun 2025	31st Mar 2025	30th Jun 2024	31st Mar 2025
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
I	Revenue from operations	52,096	62,296	49,296	2,17,365	59,051	67,676	55,534	2,38,703
II	Other income	39	171	10	1,357	31	187	111	1,636
III	Total Income ( I + II )	52,134	62,467	49,307	2,18,723	59,082	67,863	55,645	2,40,339
IV	Expenses :								
	(a) Cost of materials consumed	33,381	35,012	32,549	1,35,388	35,725	37,378	34,665	1,43,384
	(b) Purchase of stock-in-trade	1,121	1,349	942	4,434	2,861	2,313	1,754	8,434
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,265)	4,109	(1,009)	2,200	(1,247)	3,864	(551)	1,946
	(d) Employee benefits expense	2,329	2,340	2,067	8,525	3,080	3,135	2,643	11,210
	(e) Finance costs	682	748	746	2,968	856	916	871	3,587
	(f) Depreciation and amortisation expense	1,227	1,221	1,171	4,779	1,472	1,488	1,338	5,578
	(g) Other expenses	10,134	10,621	9,326	40,554	11,224	11,655	10,528	45,023
	Total expenses (IV)	47,610	55,399	45,791	1,98,847	53,971	60,748	51,247	2,19,162
V	Profit before exceptional items and tax (III - IV)	4,525	7,067	3,516	19,875	5,111	7,115	4,398	21,177
VI	Exceptional items	-	-	-	-	-	-	-	-
VII	Profit before tax (V - VI)	4,525	7,067	3,516	19,875	5,111	7,115	4,398	21,177
VIII	Tax Expenses :								
	Provision for taxation - Current	950	2,000	775	4,825	1,035	2,093	1,002	5,174
	- Earlier year	(1,489)	(1,031)	-	(1,031)	(1,489)	(1,056)	-	(1,056)
	Provision for deferred taxation	200	(50)	50	350	168	(198)	69	250
	Total tax expenses (VIII)	(339)	919	825	4,144	(286)	838	1,071	4,367
IX	Profit / (Loss) for the Year ( VII - VIII )	4,864	6,148	2,691	15,731	5,397	6,277	3,327	16,810
X	Other Comprehensive Income								
	Item that will not to be reclassified to statement of Profit and Loss								
	Fair value changes on Investments, net	-	209	-	209	-	209	-	209
	Remeasurement of defined benefit Liability/Assets, net	-	(96)	-	(96)	-	(112)	-	(112)
	Foreign currency translation reserve	-	-	-	-	-	-	-	-
	Total Other Comprehensive Income, net	-	113	-	113	11	32	42	62
XI	Total Comprehensive Income for the Year (IX+X)	4,864	6,261	2,691	15,844	5,408	6,405	3,369	16,969
XII	Weighted average number of equity shares used for computing earning per share (face value of Rs.10 each)	9,127	9,127	9,194	9,127	9,127	9,127	9,194	9,127
	Profit attributable to :								
	Owner of the Company	4,864	6,148	2,691	15,731	5,391	6,286	3,324	16,816
	Non- Controlling Interest	-	-	-	-	6.24	(9.15)	2.89	-6.15
	Total Comprehensive Income attributable to :								
	Owner of the Company	4,864	6,261	2,691	15,844	5,402	6,413	3,364	16,972
	Non- Controlling Interest	-	-	-	-	6.81	(7.56)	4.99	-3.03
XIII	Earning per equity share ( in Rs. ) (not annualised)								
	(1) Basic	5.33	6.74	2.93	17.18	5.91	6.88	3.62	18.35
	(2) Diluted	5.33	6.74	2.93	17.18	5.91	6.88	3.62	18.35

### Notes :

- The above results for the Quarter ended 30th June, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 18th July, 2025.
- The company has completed the buyback of 6,65,000 equity shares of face value of Rs.10/- representing up to 0.72% of the total number of Equity Shares of the Company at a price of Rs. 900/- per Equity Share (including premium of Rs. 890/- per Equity Share) payable in cash for an aggregate amount of up to Rs. 59,85,00,000/- (excluding filing fees payable to the SEBI, advisors' fees, stock exchanges fee for usage of their platform for Buyback, transaction costs viz. brokerage, applicable taxes inter alia including Buyback tax, securities transaction tax, GST, stamp duty, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses etc.) ("Buyback Size") on September 24, 2024. Post buyback Paid up Share Capital of the Company reduced to Rs. 91,27,00,000 divided into 9,12,70,000 Equity Shares of Rs.10/- each.
- As on June 30, 2025 the Company, has 3 (three) subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, Pinnacle Chile SpA and 1 (one) step down subsidiary, namely Pharma Go SpA.
- Company has only one business segment i.e. pharmaceuticals.
- Figures for the previous Quarter have been regrouped or rearranged wherever necessary.
- The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.co.in and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors.



For AARTI DRUGS LIMITED

Rashesh C Gogri  
( Managing Director )  
DIN: 00066291

Place: Mumbai  
Date: 18th July 2025



## **Independent Auditors' Report on Audit of Standalone Financial Results**

To  
Board of Directors,  
Aarti Drugs Limited.

### **Report on Audit of Standalone Financial Results**

#### **Opinion**

We have audited the accompanying standalone financial results of Aarti Drugs Limited ("the Company") for quarter ended 30 June 2025 ("the financial results") attached herewith being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these financial results:

1. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
2. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS-34") prescribed under section 133 of the Companies Act 2013 read with relevant rules thereunder and other accounting principles generally accepted in India of the net profit and total other comprehensive income, and other financial information of the Company for quarter ended 30 June 2025.

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone financial results.

#### **Management's Responsibilities for the Standalone Financial Results**

These quarterly standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial





controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management and the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management and the Board of Directors in terms of requirements specified under regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the Company to express an opinion on the financial results.



Materiality is the magnitude of misstatements in the standalone financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For Gokhale & Sathe,  
Chartered Accountants,  
Firm Registration No.: 103264W



Ravindra More  
Partner  
Membership No. 153666  
UDIN: 25153153666BMLYJP8465



Date: 18 July 2025  
Place: Mumbai

## **Independent Auditors' Report on Audit of Consolidated Financial Results**

To,  
Board of Directors,  
Aarti Drugs Limited

### **Report on Audit of Consolidated Financial Results**

#### **Opinion**

We have audited the accompanying consolidated financial results of Aarti Drugs Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred as "the Group") for quarter ended 30 June 2025 ("the financial results") attached herewith being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiaries (refer other matter paras), the Statement:

1. include the results of the following subsidiaries:
  - i. Pinnacle Life Science Private Limited
  - ii. Aarti Specialty Chemical Limited
  - iii. Pinnacle Chile SpA (includes Pharma Go SpA, wholly owned subsidiary of Pinnacle Chille SpA – w.e.f. 27 November 2024)
2. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
3. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS-34") prescribed under section 133 of the Companies Act 2013 read with relevant rules thereunder and other accounting principles generally accepted in India of the consolidated net profit and consolidated total other comprehensive income and other financial information of the Group for quarter ended 30 June 2025.

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.





### **Management's Responsibilities for the Consolidated Financial Results**

These quarterly consolidated financial results have been prepared on the basis of the interim financial statements. The Holding Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also include maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial results, the respective management and the Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective management and the Board of Directors either intends to liquidate the entity or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

### **Auditors' Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.





- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management and the Board of Directors in terms of requirements specified under regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results / financial information of the entities within the Group, to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the consolidated financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under regulation 33(8) of the listing regulations, as amended, to the extent applicable.






## Other Matters

### 1) Financial Results of Subsidiaries not audited by us.

The consolidated financial results include the reviewed financial results of one of the foreign subsidiary, whose interim financial Results / financial information reflect total revenues of Rs. 1,910.51 lakhs and total net profit after tax of Rs. 124.78 lakhs for the quarter ended 30 June 2025 as considered in the consolidated financial results, which have been reviewed by their respective independent auditors. The independent auditors' reports on Interim Financial Results / financial information of these entities have been furnished to us and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this entity, is based solely on the report of such auditor and the procedures performed by us are as stated in paragraph above.

Our conclusion is not modified in respect of this matter.

For Gokhale & Sathe,  
Chartered Accountants,  
Firm Registration No.: 103264W



Ravindra More  
Partner  
Membership No. 153666  
UDIN: 25153666BMLYJQ5736

Date: 18 July 2025  
Place: Mumbai